title: Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder.
abstract: The efficacy and safety of haloperidol, lithium carbonate, and placebo were critically assessed in 61 treatment-resistant, hospitalized children aged 5.2 to 12.9 years with diagnoses of conduct disorder, aggressive type. In this double-blind and well-controlled study, the optimal dosages of haloperidol ranged from 1.0 to 6.0 mg/day and those of lithium carbonate from 500 to 2,000 mg/day. For the assessment of behavioral changes and untoward effects, various rating scales were used in different settings. Both haloperidol and lithium carbonate were found to be significantly superior to placebo in decreasing behavioral symptoms. Although both medications were clinically effective, haloperidol was associated more often with untoward effects than was lithium carbonate.
mesh_terms: D000374:Aggression / Q000187:drug effects*; D002648:Child; D002653:Child Behavior Disorders / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D004421:Dystonia / Q000139:chemically induced; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D008094:Lithium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016651:Lithium Carbonate; D008297:Male; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D011581:Psychological Tests; D012890:Sleep
chemical_list: D010919:Placebos; D016651:Lithium Carbonate; D008094:Lithium; D006220:Haloperidol